Importance of "health foods", EPA and DHA, for preventive medicine

Kazunaga Yazawa

研究成果: Article

2 引用 (Scopus)

抄録

The "lifestyle-related disease" has been increasing in Japan as the population advances in age and the food culture becomes westernized. Although prevention, treatment and therapy for this disease have been attempted using certain kinds of food and nutritive elements, so-called "health foods" such as DHA and EPA, which are mostly contained in fish oil, have been a special focus within these attempts. There have been many reports regarding the pharmacological functions and the mechanisms of DHA and EPA. Also, in the past few years, it has become possible to produce ingestible DHA and EPA oils, oils for chemical compounds, oils for animal feed, and highly purified DHA and EPA for medical and pharmaceutical use. EPA ethyl ester has a wide market as a preventive medicine in Japan. Initially in 1990, this medicine was administered in cases of arterisclerosis obliterans, using its anti-platelet aggregation ability. Four years later, in 1994, its effectiveness in triglyceride reduction was recognized, and its application was extended to cases of hyperlipidemia, which has remarkably broadened its market. Clinical studies with DHA have shown improvement in senile dementia (cerebral thrombosis, Alzheimer's disease), atopic dermatitis, and the ability to focus on moving objects, as well as control of aggressiveness against others caused by stress, and prevention of hyperlipidemia, hypertension, and cancer.

元の言語English
ページ(範囲)249-253
ページ数5
ジャーナルRinsho byori. The Japanese journal of clinical pathology
52
発行部数3
出版物ステータスPublished - 2004
外部発表Yes

Fingerprint

Preventive Medicine
Oils
Aptitude
Hyperlipidemias
Food
Japan
Health
Alzheimer Disease
Intracranial Thrombosis
Fish Oils
Atopic Dermatitis
Platelet Aggregation
Life Style
Esters
Triglycerides
Medicine
Pharmacology
Hypertension
Pharmaceutical Preparations
Population

これを引用

Importance of "health foods", EPA and DHA, for preventive medicine. / Yazawa, Kazunaga.

:: Rinsho byori. The Japanese journal of clinical pathology, 巻 52, 番号 3, 2004, p. 249-253.

研究成果: Article

@article{aac309e2bfcd4b0d92767f5918d9e47a,
title = "Importance of {"}health foods{"}, EPA and DHA, for preventive medicine",
abstract = "The {"}lifestyle-related disease{"} has been increasing in Japan as the population advances in age and the food culture becomes westernized. Although prevention, treatment and therapy for this disease have been attempted using certain kinds of food and nutritive elements, so-called {"}health foods{"} such as DHA and EPA, which are mostly contained in fish oil, have been a special focus within these attempts. There have been many reports regarding the pharmacological functions and the mechanisms of DHA and EPA. Also, in the past few years, it has become possible to produce ingestible DHA and EPA oils, oils for chemical compounds, oils for animal feed, and highly purified DHA and EPA for medical and pharmaceutical use. EPA ethyl ester has a wide market as a preventive medicine in Japan. Initially in 1990, this medicine was administered in cases of arterisclerosis obliterans, using its anti-platelet aggregation ability. Four years later, in 1994, its effectiveness in triglyceride reduction was recognized, and its application was extended to cases of hyperlipidemia, which has remarkably broadened its market. Clinical studies with DHA have shown improvement in senile dementia (cerebral thrombosis, Alzheimer's disease), atopic dermatitis, and the ability to focus on moving objects, as well as control of aggressiveness against others caused by stress, and prevention of hyperlipidemia, hypertension, and cancer.",
author = "Kazunaga Yazawa",
year = "2004",
language = "English",
volume = "52",
pages = "249--253",
journal = "Rinsho byori. The Japanese journal of clinical pathology",
issn = "0047-1860",
publisher = "Nihon Rinsho Byori Gakkai",
number = "3",

}

TY - JOUR

T1 - Importance of "health foods", EPA and DHA, for preventive medicine

AU - Yazawa, Kazunaga

PY - 2004

Y1 - 2004

N2 - The "lifestyle-related disease" has been increasing in Japan as the population advances in age and the food culture becomes westernized. Although prevention, treatment and therapy for this disease have been attempted using certain kinds of food and nutritive elements, so-called "health foods" such as DHA and EPA, which are mostly contained in fish oil, have been a special focus within these attempts. There have been many reports regarding the pharmacological functions and the mechanisms of DHA and EPA. Also, in the past few years, it has become possible to produce ingestible DHA and EPA oils, oils for chemical compounds, oils for animal feed, and highly purified DHA and EPA for medical and pharmaceutical use. EPA ethyl ester has a wide market as a preventive medicine in Japan. Initially in 1990, this medicine was administered in cases of arterisclerosis obliterans, using its anti-platelet aggregation ability. Four years later, in 1994, its effectiveness in triglyceride reduction was recognized, and its application was extended to cases of hyperlipidemia, which has remarkably broadened its market. Clinical studies with DHA have shown improvement in senile dementia (cerebral thrombosis, Alzheimer's disease), atopic dermatitis, and the ability to focus on moving objects, as well as control of aggressiveness against others caused by stress, and prevention of hyperlipidemia, hypertension, and cancer.

AB - The "lifestyle-related disease" has been increasing in Japan as the population advances in age and the food culture becomes westernized. Although prevention, treatment and therapy for this disease have been attempted using certain kinds of food and nutritive elements, so-called "health foods" such as DHA and EPA, which are mostly contained in fish oil, have been a special focus within these attempts. There have been many reports regarding the pharmacological functions and the mechanisms of DHA and EPA. Also, in the past few years, it has become possible to produce ingestible DHA and EPA oils, oils for chemical compounds, oils for animal feed, and highly purified DHA and EPA for medical and pharmaceutical use. EPA ethyl ester has a wide market as a preventive medicine in Japan. Initially in 1990, this medicine was administered in cases of arterisclerosis obliterans, using its anti-platelet aggregation ability. Four years later, in 1994, its effectiveness in triglyceride reduction was recognized, and its application was extended to cases of hyperlipidemia, which has remarkably broadened its market. Clinical studies with DHA have shown improvement in senile dementia (cerebral thrombosis, Alzheimer's disease), atopic dermatitis, and the ability to focus on moving objects, as well as control of aggressiveness against others caused by stress, and prevention of hyperlipidemia, hypertension, and cancer.

UR - http://www.scopus.com/inward/record.url?scp=3042676596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042676596&partnerID=8YFLogxK

M3 - Article

C2 - 15137325

AN - SCOPUS:3042676596

VL - 52

SP - 249

EP - 253

JO - Rinsho byori. The Japanese journal of clinical pathology

JF - Rinsho byori. The Japanese journal of clinical pathology

SN - 0047-1860

IS - 3

ER -